Pulse Biosciences, Inc (PLSE) News
Filter PLSE News Items
PLSE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PLSE News Highlights
- For PLSE, its 30 day story count is now at 2.
- Over the past 17 days, the trend for PLSE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest PLSE News From Around the Web
Below are the latest news stories about PULSE BIOSCIENCES INC that investors may wish to consider to help them evaluate PLSE as an investment opportunity.
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac CatheterHAYWARD, Calif., December 20, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. All patients were successfully discharged by treating physicians. Patients will continue to be monitored and |
Executive Chairman of Pulse Biosciences Robert Duggan Buys More StockPulse Biosciences, Inc. ( NASDAQ:PLSE ) shareholders (or potential shareholders) will be happy to see that the... |
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous ElectrodeHAYWARD, Calif., November 21, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA percutaneous electrode. |
Chief Strategy Officer of Pulse Biosciences Picks Up 24% More StockInvestors who take an interest in Pulse Biosciences, Inc. ( NASDAQ:PLSE ) should definitely note that the Chief... |
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare ConferenceHAYWARD, Calif., November 15, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York. |
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call TranscriptPulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Philip Taylor, Investor Relations. Thank you. You may begin. Philip Taylor: Thank […] |
Q3 2023 Pulse Biosciences Inc Earnings CallQ3 2023 Pulse Biosciences Inc Earnings Call |
Pulse Biosciences Inc (PLSE) Reports Decrease in Q3 Losses and Advances in Cardiac Device ...Financial and Business Highlights from Pulse Biosciences' Third Quarter 2023 Earnings |
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial ResultsHAYWARD, Calif., November 13, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the third quarter ended September 30, 2023. |
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference CallHAYWARD, Calif., November 10, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will now report financial results for the third quarter of 2023 before market opens on Monday, November 13, 2023. Company management will now host a corresponding conference call beginning at 9:00am PT / 12:00pm ET. |